Search research articles
Contact Us
Filters
Showing results (11-20 of 151) with videos related to
Page
of 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2012
Before we throw out progression-free survival as a valid end point
David J Stewart
The Oncologist
|
December 24, 2004
Foreword--new directions for topotecan in lung cancer treatment
David J Stewart
Critical Reviews in Oncology/Hematology
|
January 6, 2010
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
David J Stewart
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2008
Gefitinib maintenance in stage III non-small-cell lung cancer
David J Stewart
Oncotarget
|
January 7, 2016
Click chemistry, 3D-printing, and omics: the future of drug development
Razelle Kurzrock, David J Stewart
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Cancer: the road to Amiens
David J Stewart, Razelle Kurzrock
BMC Cancer
|
April 17, 2013
Fool's gold, lost treasures, and the randomized clinical trial
David J Stewart, Razelle Kurzrock
Oncology (Williston Park, N.Y.)
|
April 16, 2008
Systemic therapy for lung cancer brain metastases: a rationale for clinical trials
Yun Oh, David J Stewart
The Oncologist
|
March 5, 2013
Compliance in early-phase cancer clinical trials research
Razelle Kurzrock, David J Stewart
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2016
Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients
Razelle Kurzrock, David J Stewart
Page
of 16
Search research articles
Search
Showing results (11-20 of 151) with videos related to
Sort By:
Page
of 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2012
Before we throw out progression-free survival as a valid end point
David J Stewart
The Oncologist
|
December 24, 2004
Foreword--new directions for topotecan in lung cancer treatment
David J Stewart
Critical Reviews in Oncology/Hematology
|
January 6, 2010
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
David J Stewart
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2008
Gefitinib maintenance in stage III non-small-cell lung cancer
David J Stewart
Oncotarget
|
January 7, 2016
Click chemistry, 3D-printing, and omics: the future of drug development
Razelle Kurzrock, David J Stewart
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Cancer: the road to Amiens
David J Stewart, Razelle Kurzrock
BMC Cancer
|
April 17, 2013
Fool's gold, lost treasures, and the randomized clinical trial
David J Stewart, Razelle Kurzrock
Oncology (Williston Park, N.Y.)
|
April 16, 2008
Systemic therapy for lung cancer brain metastases: a rationale for clinical trials
Yun Oh, David J Stewart
The Oncologist
|
March 5, 2013
Compliance in early-phase cancer clinical trials research
Razelle Kurzrock, David J Stewart
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2016
Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients
Razelle Kurzrock, David J Stewart
Page
of 16